AI Tool Approved to Tackle Australia's Low Lung Cancer Survival Rates

OXFORD, England – February 26, 2026 – Australian health officials have given regulatory approval to a sophisticated artificial intelligence platform designed to help doctors detect lung cancer earlier, a move that could significantly impact the nation's battle against its deadliest cancer.

The Therapeutic Goods Administration (TGA) granted Class IIb approval to Optellum's Virtual Nodule Clinic (VNC), an AI-enabled software that assists clinicians in identifying and managing potentially cancerous pulmonary nodules found on CT scans. The approval paves the way for the technology's rollout in Australian hospitals and clinics, offering a new tool to address the country's persistently low lung cancer survival rates.

A New Weapon in a Critical Fight

Lung cancer represents a major public health crisis in Australia. More than 15,000 new cases are diagnosed each year, and the disease is the leading cause of cancer-related death. The five-year survival rate hovers at a grim 27%, a figure largely attributed to diagnoses occurring at late stages when the cancer has already spread and treatment options are limited.

The press release from Optellum highlights the systemic challenges that contribute to these outcomes, including the "delayed detection of incidental findings, inconsistent follow-up, and growing pressure on imaging and specialist services." These issues can lead to missed opportunities for life-saving early intervention and create profound anxiety for patients awaiting a clear diagnosis.

Optellum's VNC platform is engineered to address these very pain points. The system uses a clinically validated AI algorithm, known as Lung Cancer Prediction (LCP), to analyze CT scans and provide a risk score for lung nodules. This helps radiologists and pulmonologists to more effectively triage cases, prioritizing patients with high-risk nodules for immediate follow-up and further diagnostic tests, while potentially reducing unnecessary invasive procedures for those with low-risk findings.

Company materials emphasize that the technology is a decision-support tool, designed to augment, not replace, the expertise of clinicians. This "human-in-the-loop" approach is critical for gaining acceptance within the medical community and aligns with guidance from leading medical bodies.

Perfect Timing for a National Push

The TGA's approval comes at a pivotal moment for lung cancer care in Australia. In July 2025, the country launched its first National Lung Cancer Screening Program (NLCSP), a government-funded initiative offering low-dose CT scans to high-risk individuals. The program is projected to screen over 260,000 eligible Australians in its first year alone, a massive undertaking expected to prevent thousands of deaths over the next decade.

However, this national screening effort will generate an unprecedented volume of medical images, placing immense pressure on Australia's radiology workforce. Efficiently and accurately interpreting hundreds of thousands of scans is a logistical and clinical challenge.

AI solutions like the Virtual Nodule Clinic are poised to become essential infrastructure for the NLCSP's success. By automating the initial analysis and helping to flag suspicious nodules, the platform can streamline workflows, improve consistency in reporting, and ensure that the most urgent cases are not lost in the deluge of data. This allows specialists to focus their time and expertise where it is needed most, potentially accelerating the entire diagnostic pathway from detection to treatment.

Navigating a Competitive and Cautious Market

Optellum enters a market that is both promising and increasingly competitive. The Australian healthcare system is showing a growing receptiveness to AI, but it is not an empty field. Several other companies are already deploying or seeking approval for similar AI-driven diagnostic tools.

ParagonCare, an Australian provider, recently partnered with Coreline Soft to introduce its AI lung cancer screening software. Meanwhile, the locally developed Annalise.ai is already being used to enhance chest x-ray analysis in some of the country's largest screening setups. These developments indicate a vibrant ecosystem for medical AI, one where robust clinical evidence and seamless integration will be key differentiators.

The regulatory environment is also maturing. The TGA has been proactive in establishing clear guidelines for AI-enabled medical devices, ensuring that any tool used in clinical practice has undergone rigorous review for safety and performance. This framework provides a pathway for innovation while safeguarding patient welfare.

Australia's leading medical associations, including the Royal Australian and New Zealand College of Radiologists (RANZCR), have expressed cautious optimism about AI's role in medicine. They champion its potential to improve outcomes and alleviate workforce pressures but stress the non-negotiable need for human oversight, ethical deployment, and local validation. The emphasis remains on ensuring that the final clinical decision always rests with a human expert, a principle that Optellum's platform is designed to uphold.

From Global Validation to Local Impact

The TGA approval is the latest in a series of regulatory milestones for the Oxford-based company, which has successfully navigated the complex approval processes in the world's largest healthcare markets. Its VNC platform is already FDA-cleared in the United States, CE-MDR marked in the European Union, and UKCA marked in the United Kingdom. This track record of global compliance lends significant credibility as Optellum expands into Australia.

The company's technology is supported by a body of real-world evidence and peer-reviewed studies. Independent research has demonstrated that its LCP AI can outperform conventional risk prediction models, improving both the sensitivity and specificity of lung nodule assessment. Some studies suggest the tool could lead to earlier diagnosis in a significant percentage of both cancerous and benign nodules, helping to fast-track treatment for those who need it and provide peace of mind for those who do not.

A real-world study at several U.S. hospitals found that implementing a commercial AI tool was associated with a significant increase in patient throughput and a rise in the number of lung cancers diagnosed, particularly at early, more treatable stages. By creating a more consistent and streamlined care pathway, the technology helped narrow the time-to-diagnosis window for many patients.

For thousands of Australians who will be diagnosed with lung cancer in the coming years, the responsible integration of such validated AI tools offers new hope. By empowering clinical teams to work with greater speed, clarity, and confidence, this technology has the potential to turn the tide against one of the nation's most formidable health challenges.